Sept 28 (Reuters) - Roche Holding AG:
* FDA APPROVES GENENTECH’S XOLAIR (OMALIZUMAB) PREFILLED SYRINGE FORMULATION
* GENENTECH SAYS NEW XOLAIR PFS FORMULATION IS EXPECTED TO BE AVAILABLE BY END OF THIS YEAR IN U.S Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)